British pharmaceutical company AstraZeneca has rejected US drug maker Pfizer's latest £50 share offer. Lex's Robert Armstrong and Joseph Cotterill examine the cost and tax savings implied in the bid.
For more video content from the Financial Times, visit http://www.FT.com/video
Subscribe to the Financial Times on YouTube; http://goo.gl/vUQx5k
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes
